Kyverna Therapeutics’ stock rose 25.9% in one month and 177.6% over 52 weeks, reaching a $602.48 million market cap.
Kyverna Therapeutics (NASDAQ:KYTX) closed at $9.91 per share on July 8, 2026, reflecting a market capitalization of $602.48 million. The biopharmaceutical company, focused on cell therapies for autoimmune diseases, posted a 25.92% return over the past month and a 177.59% gain over the last 52 weeks.
Investor interest in AI-driven innovation and portfolio adjustments contributed to the stock’s performance. The firm’s late-stage pipeline has drawn attention amid broader market optimism about biotech advancements. Prior to this rally, the stock had experienced volatility tied to macroeconomic concerns and sector rotation.
Jacob Funds highlighted Kyverna Therapeutics in its April 2026 investor letter, citing potential in its therapeutic developments. The fund’s optimism aligns with growing investor focus on high-growth biotech stocks.